The General Practitioners Research Institute aims to improve the lives of patients by facilitating participation in studies that investigate diagnosis and long term effects of (pharmaceutical) treatment for chronic diseases in primary care or preventive (screening) programs.
The Unmet need
The evidence for pharmaceutical interventions in any chronic disease comes mostly from secondary care or tertiary care in highly selected patients for research. However, in many countries, chronic diseases are primarily treated in primary care. Since patients with chronic diseases in secondary care are often referred for their complexity, we know little about the large group of ordinary patients and their reaction on treatment in real life. This means that there is a lack of evidence regarding the treatment of the ordinary patient in primary care.
The lack of real world evidence is acknowledged, but actual conduction of real world studies in primary care can be challenging. With lack of time and experience for the administrative burden of trials, GP’s are hesitant to participate. Since GP practices are small, sponsors and CRO’s are hesitant to use GP practices, as multiple GP practices have to be approached to reach the required sample size.
This is where GPRI comes in. GPRI facilitates GP practices, lowering the threshold for study participation, and ensuring the unmet need is solved.
The GPRI is based on the experience and knowledge of the GRIAC primary care research group who have extended experience in developing primary care tools such as the Clinical COPD Questionnaire (CCQ), conducting clinical trials, and performing health economic studies. Currently, the GPRI network has over 80,000 patients we can include in research.
Why the Netherlands?
The Netherlands is particularly well suited for real world evidence studies, with a well-developed primary care system, highly trained GPs, evidence-based protocols, and GP practices with listed patients and good electronic patient registration systems.